Abstract Number: 0616 • ACR Convergence 2025
Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
Background/Purpose: Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently represent a diagnostic challenge due to its heterogeneous manifestations. Neurofilament light chain (NfL)…Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…Abstract Number: 0363 • ACR Convergence 2025
Assessing Whole Health Needs in Systemic Lupus Erythematosus
Background/Purpose: Care models that take a ‘Whole Health’ perspective by emphasizing personalized care focused on the individual’s values, needs, and goals, rather than solely on…Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…Abstract Number: 2645 • ACR Convergence 2025
Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Background/Purpose: Current estimates for age of SLE onset are limited, particularly for males and racial/ethnic groups in the United States. Leveraging five Centers for Disease…Abstract Number: 2559 • ACR Convergence 2025
Increasing Clinical Trial Awareness in Sample of Underrepresented Systemic Lupus Erythematosus Patients
Background/Purpose: Underrepresented Systemic Lupus Erythematosus (SLE) patients are greatly underrepresented in SLE clinical trials. We aimed to increase clinical trial awareness with various interventions in…Abstract Number: 2455 • ACR Convergence 2025
Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with persistent fatigue. Physical activity (PA) & dietary intake are potential modifiable behaviors that can reduce fatigue in…Abstract Number: 2438 • ACR Convergence 2025
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…Abstract Number: 2419 • ACR Convergence 2025
Dried Blood Spots for Remote ANA and Autoantibody Screening
Background/Purpose: Antinuclear antibody (ANA) and SLE-related autoantibody testing are integral parts of SLE screening, diagnosis, and monitoring. However, these tests rely on access to phlebotomy…Abstract Number: 2401 • ACR Convergence 2025
Associations between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-Protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
Background/Purpose: Serum levels of soluble urokinase plasminogen activator receptor (suPAR) have been associated with organ damage accumulation in patients with recent-onset systemic lupus erythematosus (SLE).…Abstract Number: 2386 • ACR Convergence 2025
Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the heart. Recent studies attribute…Abstract Number: 2219 • ACR Convergence 2025
Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
Background/Purpose: Recurrent pregnancy loss (RPL) and unexplained infertility (UIF) are significant reproductive health challenges in patients with systemic lupus erythematosus (SLE). SLE causes systemic inflammation…Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…Abstract Number: 1859 • ACR Convergence 2025
Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)”
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases vulnerability to malignancy and premature mortality. Understanding long-term trends and disparities in SLE-related…
ACR Meeting Abstracts